不同剂量的抗孕-53和18-甲基炔诺酮对大鼠垂体机能反应性影响的比较

为了研究甾体避孕药对垂体生殖激素的影响,本实验以动情前期大鼠受二次静脉注射GnRH诱发的LH激发效应(priming effect)为模型,观察经肌肉注射不同类型、不同剂量的避孕药(抗孕-53或18-甲基炔诺酮)后垂体对GnRH的敏感性反应。抗孕-53的剂量为3,1.5,0.75,0.375和0.19mg;l8-甲基炔诺酮的剂量为4,1和0.5mg,各溶于0.5ml茶油;对照组为0.5ml茶油。实验结果表明,不同剂量的抗孕-53均促进血浆LH浓度升高,其中以3mg组的反应最显著,与对照组比较P<0.01。不同剂量的18-甲基炔诺酮对垂体敏感性均有显著的抑制作用,使血浆LH浓度降低(P<0.01)。大鼠经肌肉注射乙炔雌二醇21μg和10.5μg后,其垂体对GnRH的反应也有促进作用,但不能完全模拟抗孕-53的效应。上述结果表明,不同类型的甾体避孕药能增加或降低大鼠垂体对GnRH的敏感性。     

光照对鸡生长、产蛋及血浆雌二醇、黄体生成素、甲状腺素的影响

70日龄星杂“579”小母鸡120只,随机分成A、B、C三组。C组为对照组。A、B两组分别以32和8Lx的强度补充光照,使其每天的光照时间达14h。从70日龄起,每10天称重一次;从开产日龄起,对每只鸡的产蛋分别按日龄称重、登记。结果表明,光照强度与鸡的生长速度和平均蛋重相关不显著,而与鸡的性成熟和产蛋量显著相关。用放射免疫分析法测定了三组鸡100～180日龄间外周血浆E_2、LH和T_4含量,B组鸡LH峰值最高,其峰值(149日龄)与基础值(100日龄)对比,增长率为231.4％;A组鸡血浆T_4水平增加明显,但其产蛋量相对较低;补充光照组能促使血浆E_2峰值的出现早于自然光照组,但各组鸡E_2峰值无显著差异。     

酪氨酸对男子血清促性腺激素和睾酮浓度的影响

给成年男子(n=5)口服酪氨酸300mg/日,共6天,第四天肌注 LRH-A 150μg/人,用RIA 法测定其血清 LH、FSH 和睾酮浓度。与对照组(n=5)相比,酪氨酸对 LH 和 FSH 的基础水平和 LRH-A 诱发的 LH 峰和 FSH 峰均无明显影响。睾酮的基础水平稍有升高,而酪氨酸对 LRH-A 引起的睾酮水平升高有明显的抑制作用。结果提示,酪氨酸可不通过垂体而直接作用于睾丸以影响睾酮的分泌。     

阉割和睾丸酮替代对雄性老年大鼠下丘脑和血浆促黄体生成素释放激素水平的影响

应用放射免疫分析(RIA)技术比较了年青(2—3月龄)和老年(24—26月龄)雄性大鼠下丘脑和血浆促黄体生成素释放激素(LHRH)水平及其在睾丸切除(ORDX)和睾丸酮(T)替代下LHRH水平的变化。老年大鼠血浆T水平明显降低,下丘脑LHRH含量亦呈明显下降趋势,但血浆LHRH水平与年青大鼠十分接近。在ORDX和T替代下,两组动物血浆T水平没有明显差别,但老年大鼠下丘脑和血浆LHRH的变化率却不同程度地低于年青大鼠。上述结果提示,老年雄性大鼠下丘脑LHRH神经元系统的负反馈能力明显削弱,这也许是下丘脑-垂体-睾丸轴呈增龄性衰变的重要原因之一。     

抗孕53影响大鼠垂体前叶对GnRH的敏感性反应

本实验应用动情前期大鼠垂体前叶组织块离体培养方法,观察了 A 环失碳类甾体化合物—抗孕53对 LH 基础分泌和动员性分泌的影响。实验分为对照组、GnRH 组、抗孕53组、GnRH-抗孕53组。结果表明,GnRH 可显著促进 LH 分泌并产生自激作用。GnRH 的第一次作用后,LH 分泌增加量由对照组的0.7ng/ml 增加到4.3ng/ml,而当 GnRH 第二次作用后,这一效应显著增强,由对照组的0.5ng/ml 增加到6.8ng/ml,GnRH 的两次作用效应相比,差异极显著。抗孕53可部分抑制垂体对 GnRH 的敏感性反应。抗孕53作用后,LH 分泌增加量由 GnRH 第一次作用后的4.3减至2.5ng/ml,由 GnRH 第二次作用后的6.8降至4.1ng/ml。抗孕53不影响 LH 的基础分泌,与对照组相比,两组的 LH 分泌增加量无显著差异。抗孕53对垂体的这一作用可能是通过直接影响促性腺激素细胞的代谢及调节而实现。     

用放射免疫测定法研究性类固醇激素和棉酚对大白鼠垂体LH分泌的影响

用兔抗羊 LH 血清和放射性碘标记的羊 LH 建立了大白鼠血清中 LH 的双抗体放射免疫测定法。在这异源的系统中羊 LH 和大鼠 LH 的剂量反应曲线是平行的。当用羊LH_(2-2-1)作参考标准时测量的灵敏度为0.1ng/管。当用大鼠 LH-RP-1作参考标准时测量的灵敏度为10ng/管。大鼠的 FSH 没有交叉反应,所以 FSH 不会干扰血清 LH 的测定。用这个系统我们研究了去卵巢以及去卵巢后给予孕酮和巳烯雌酚以后大鼠血清中LH 水平的变化。结果表明性类固醇激素对大鼠垂体 LH 的分泌具有一个负反馈的调节机制。本文中还研究了棉酚对大鼠 LH 分泌的影响。我们发现成年雄鼠服用棉酚以后血浆 LH 的水平以及垂体对 LRH 的反应均无显著的变化。结果表明新的男性抗生育药物——棉酚似乎不影响垂体的 LH 分泌功能。     

香烟烟雾暴露对雄性大鼠血浆尼古丁、可替宁的影响

目的通过对吸烟大鼠血浆尼古丁、可替宁含量的测定,探讨香烟在体内的内暴露水平。方法清洁级SD雄性大鼠160只,随机分为2、4、6、8、12周的低、中、高染毒剂量组及对照组,每组10只。采用呼吸道静式染毒,每日染毒一次,染毒周期为2、4、6、8、12周。观察大鼠的一般毒性效应,运用气相色谱-质谱联用法检测吸烟大鼠血浆中尼古丁、可替宁的含量。结果香烟烟雾暴露组大鼠在第3周后逐渐开始出现间歇咳嗽,腹式呼吸加剧,鼻噪音等症状,暴露时间越长,症状越明显;染毒剂量越高,染毒周期越长,大鼠体重减少越明显,与空白对照组相比,差异有显著性(P0.01);大鼠血浆尼古丁的保留时间为7.5~8.5 min,随暴露时间的延长,暴露剂量的增加,大鼠血浆中尼古丁含量较空白对照组(155±56.65)ng/m L有所增加;大鼠血浆可替宁的保留时间为11.5~12.5 min;随暴露时间的延长,暴露剂量的增加,大鼠血浆中可替宁含量较空白对照组(340±41.97)ng/m L有所增加,且呈现剂量-反应关系,不同暴露周期间可替宁含量的差异有显著性(P0.05),且暴露时间与暴露剂量存在交互效应(P0.05)。结论香烟烟雾暴露可造成大鼠机体不同程度的损伤,大鼠血浆可替宁浓度能够有效反映香烟烟雾内暴露情况,且呈现较好的剂量-反应关系。     

凡纳滨对虾饲料中酵母水解物替代鱼粉适宜比例的研究

试验添加酵母水解物替代不同比例鱼粉, 添加量分别为0(对照组)、2.5%、5.0%、7.5%、10%和12.5%,替代鱼粉的比例分别为0、8%、16%、24%、32%和40%, 通过评估生长性能、消化酶和免疫相关酶活性等指标评价酵母水解物替代鱼粉对凡纳滨对虾健康生长的影响。选择健康凡纳滨对虾[初重(0.630.01) g]随机分为6组, 每组3个重复, 养殖8周。结果表明, Y2.5和Y5.0处理组对虾增重率和特定生长率与Y0相比差异不显著(P0.05), 但是显著高于其余各组(P0.05), Y2.5组饲料系数和Y0组相比差异不显著, 显著低于其余各组(P0.05); Y5.0组肝胰腺糜蛋白酶和Y0组相比差异不显著(P0.05), 显著高于其余各组(P0.05); Y2.5和Y7.5组胰蛋白酶和Y0组相比差异不显著, 但是显著高于其余各组(P0.05); Y2.5组与Y5.0酚氧化酶活性显著高于其余各组(P0.05), Y2.5组与Y7.5组和Y0组总一氧化氮合酶活性显著高于其余各组(P0.05), Y5.0组和Y7.5组血清溶菌酶活性显著高于其余各组(P0.05)。以增重率为判据, 经二次曲线拟合得出, 获得最大增重率时酵母水解物添加量为1.62%, 替代鱼粉比例为5.19%; 酵母水解物替代鱼粉比例达24%时不会对增重率产生显著影响。     

镉在大鼠前列腺组织内的蓄积

为比较重金属镉在去势与非去势雄性大鼠前列腺组织内蓄积量的变化,将60只健康雄性SD大鼠随机分为六组:对照组、去势对照组、低剂量镉组(2.5 mμmol·Kg^-1)、高剂量镉组(20 mμmol·Kg^-1)、去势低剂量镉(2.5 mμmol·Kg^-1)组、去势高剂量镉(20 mμmol·Kg^-1)组,18个月后取材进行实验.利用原子吸收分光光度法检测大鼠前列腺组织中重金属镉含量.与非去势对照组相比,各去势组大鼠前列腺组织内镉含量明显降低;注射镉后,大鼠前列腺组织镉含量明显高于对照组,但高、低剂量组之间无显著差别.实验表明长期镉暴露后,前列腺组织内镉含量明显增加;经去势手术的大鼠,长期镉暴露后前列腺组织内镉含量未升高,但机制并不明确.     

蓝狐发情期及妊娠期血清五种 生殖激素含量变化

为探究发情期及妊娠期雌性蓝狐(Alopex lagopus)生殖激素的变化规律,选取11只繁殖期雌性蓝狐,采用放射免疫法(RIA)测定血清中雌二醇(E2)、促黄体生成素(LH)、促卵泡素(FSH)、孕酮(P)以及催乳素(PRL)的含量。结果表明,促卵泡素和促黄体生成素在发情期及妊娠期血清中浓度一直处于较稳定水平,并呈波动式分泌,最大值分别为(2.18±0.69)U/L和(8.82±1.83)U/L,同种激素不同检测日期数据两两比较差异不显著(P> 0.05);雌二醇在发情期和妊娠期血清中浓度亦处于较稳定水平,最大值出现在发情第1天,为(27.73±23.19)ng/L,数据两两比较差异亦不显著(P> 0.05);孕酮在发情期维持较高水平,最大值在发情第3天,为(2.41±1.35)μg/L,之后在妊娠期持续下降,分娩当天达到最低点,为(0.13±0.14)μg/L,数据两两比较差异显著(P <0.05);催乳素在发情期先下降,最低值为(0.15±0.04)U/L,第3天开始升高,并在妊娠期保持较高水平,到分娩时维持最高(0.21±0.05)U/L,数据两两比较差异不显著(P> 0.05)。初步探索了5种激素含量在发情和妊娠期间的动态变化,为养殖蓝狐的生殖生理提供参考数据。     

Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design

Ligands occupy the core of nuclear receptor (NR) ligand binding domains (LBDs) and modulate NR function. X-ray structures of NR LBDs reveal most NR agonists fill the enclosed pocket and promote packing of C-terminal helix 12 (H12), whereas the pockets of unliganded NR LBDs differ. Here, we review evidence that NR pockets rearrange to accommodate different agonists. Some thyroid hormone receptor (TR) ligands with 5′ extensions designed to perturb H12 act as antagonists, but many are agonists. One mode of adaptation is seen in a TR/thyroxine complex; the pocket expands to accommodate a 5′ iodine extension. Crystals of other NR LBDs reveal that the pocket can expand or contract and some agonists do not fill the pocket. A TRβ structure in complex with an isoform selective drug (GC-24) reveals another mode of adaptation; the LBD hydrophobic interior opens to accommodate a bulky 3′ benzyl extension. We suggest that placement of extensions on NR agonists will highlight unexpected areas of flexibility within LBDs that could accommodate extensions; thereby enhancing the selectivity of agonist binding to particular NRs. Finally, agonists that induce similar LBD structures differ in their activities and we discuss strategies to reveal subtle structural differences responsible for these effects.     

Structure activity studies of the serine-AIB dipeptide domain in 2,3-dihydroisothiazole based growth hormone secretagogues

A series of growth hormone secretagogues (GHSs) based on 2,3-dihydroisothiazole has been synthesized in the search for a potential treatment of growth hormone deficiency or frailty in the elderly. This paper describes the evaluation of the SAR of the benzyl-d-Ser-aminoisobutyric acid dipeptide fragment. Introduction of substituents in the peptide backbone and in the phenyl ring has been investigated, as well as replacements for the benzyl group and for the AIB residue. A number of modifications resulted in enhanced potency over the parent benzyl-d-Ser-AIB derivative.     

Production of a biologically active novel goldfish growth hormone in Escherichia coli

Goldfish pituitary contains two types of growth hormones. One with five cysteine residues (type-I) similar to other Cyprinid GHs, and the other with four Cys residues (type-II) similar to those of other fish and tertapod species. Recombinant goldfish type II GH (gfGH-II) was produced in Escherichia coli using the pRSETB expression vector. The gfGH-II was produced fused to a leader sequence, which sequestered into inclusion bodies after expression. The inclusion bodies were solubilized using sodium hydroxide and the fusion protein purified by chelating affinity chromatography. Subsequently, gfGH-II was cleaved and analyzed by Western blotting, using a specific antiserum. For comparison we also produced recombinant common carp GH (cGH) which has 95% similarity to gfGH-II, and tested their growth promoting activity in goldfish. Both forms of GH significantly increased the growth rate of goldfish (P<0.05), although cGH was found to have a somewhat higher potency than gfGH-II.     

Higher molecular weight immunoreactive species of luteinizing hormone releasing hormone: possible precursors of the hormone.

Separation of extracts of sheep hypothalami on Sephadex G-25 gave three peaks exhibiting luteinizing hormone releasing hormone immunoreactivity. One peak corresponded in elution volume with luteinizing hormone releasing hormone but the others (I and II) eluted earlier, indicating that they are of higher molecular weight. Elution volumes were unaffected by 8 M urea treatment. Incubation of I and II with hypothalamic peptidases produced a small quantity of immunoreactive material eluting in the luteinizing hormone releasing hormone region. Digestion of I with trypsin resulted in a marked increase in total immunoreactivity and the production of material with the same elution volume as II. Tryptic digestion of II gave rise to a small quantity of immunoreactive peptide eluting in the luteinizing hormone releasing hormone region. The amount of I and II relative to luteinizing hormone releasing hormone was lower in the median eminence than in the supra optic chiasmatic and basal hypothalamic regions.     

Chronic orchidectomy does not influence the sensitivity of the pituitary somatotropes to varying doses of GHRH administered intravenously to the adult male rhesus monkey

In the present study, the pituitary growth hormone (GH) response to graded doses of GH-releasing hormone (GHRH) was determined in intact (n = 3) and chronically orchidectomized (n = 3) adult rhesus monkeys (Mucaca mulatta). GHRH in doses of 0, 6.25, 12.5 and 25 microg/kg BW was infused through a teflon cannula implanted in the saphenous vein. Blood samples were collected 60 min before and 90 min after the injection of the neurohormone at 15 min intervals. All bleedings were carried out under ketamine hydrochloride anesthesia. The plasma levels of GH were determined by using AutoDELFIA time-resolved flouroimmunoassay, whereas plasma levels of testosterone and estradiol were determined using specific radioimmunoassay systems. The GH responses to GHRH were not significantly different between intact and chronically orchidectomized monkeys at any of the dose levels tested (p > 0.05). The administration of GHRH resulted in a significant (p < 0.05) stimulation of GH secretion at all the doses tested and in both the groups studied. In both intact and orchidectomized animals, the greatest response was observed at 6.25 microg/kg and no further increase was noted with the higher doses of GHRH. In conclusion, the present study suggests that chronic orchidectomy does not influence the sensitivity of the pituitary somatotropes to GHRH stimulation implying that the responsiveness of the pituitary somatotropes to GHRH is independent of testicular steroid modulation.     

Specific binding of an immunoreactive and biologically active 125I-labeled N(1)acylated substance P derivative to parotid cells

A biologically active ¹²⁵I-substance P derivative (I¹²⁵-BH-substance P), prepared by conjugation of substance P with [^125I]Bolton-Hunter reagent, binds specifically to isolated rat parotid cells. The Kd is 4 nM for I-BH-substance P, 5 nM for substance P, 0.18 μM for substance P octa(4–11)peptide, and 1.6 μM for substance P [pyroglutamyl⁶]hexa(6–11)peptide. Substance P free acid and substance P penta(7–11)peptide are much weaker competitors and the C-terminal tri(9–11)peptide has no effect at 30 μM. The binding is also inhibited by 1 μM physalaemin, eledoisin and substance P methyl ester, but not by unrelated peptides. The selective inhibition of the binding by the biologically active analogs and fragments of substance P indicates that the ¹²⁵I-labeled N(1)acylated substance P derivative may interact with a substance P receptor on parotid cells.     

慢病毒载体介导GHRH基因在小鼠肌肉组织表达及对动物生长的影响

人与动物体内生长激素受生长激素释放激素(Growth Hormone Releasing Hormone,GHRH)与生长激素抑制激素(Somatostatin,SST)两种因子共同调节,在体内表达外源GHRH,可以提高体内GH基础水平,进而达到促进体内GH释放,加速动物生长的效果.对慢病毒载体系统加以改造,使之成为C...     

保幼激素的代谢

保幼激素的代谢由保幼激素酯酶、保幼激素环氧水解酶和保幼激素二醇激酶等共同催化完成。在这些代谢酶的作用下,保幼激素代谢成保幼激素酸、保幼激素二醇、保幼激素酸二醇和保幼激素二醇磷酸。作者总结了保幼激素代谢的研究方法;按实验室和昆虫种类为线索,归纳和概括了每一种保幼激素代谢酶的研究进程;对保幼激素酯酶和保幼激素环氧水解酶作了序列分析;最后对保幼激素的代谢研究进行了展望。     

Design of thyroid hormone receptor antagonists from first principles

It is desirable to obtain TR antagonists for treatment of hyperthyroidism and other conditions. We have designed TR antagonists from first principles based on TR crystal structures. Since agonist ligands are buried in the fold of the TR ligand binding domain (LBD), we reasoned that ligands that resemble agonists with large extensions should bind the LBD, but would prevent its folding into an active conformation. In particular, we predicted that extensions at the 5′ aryl position of ligand should reposition helix (H) 12, which forms part of the co-activator binding surface, and thereby inhibit TR activity. We have found that some synthetic ligands with 5′ aryl ring extensions behave as antagonists (DIBRT, NH-3), or partial antagonists (GC-14, NH-4). Moreover, one compound (NH-3) represents the first potent TR antagonist with nanomolar affinity that also inhibits TR action in an animal model. However, the properties of the ligands also reveal unexpected aspects of TR behavior. While nuclear receptor antagonists generally promote binding of co-repressors, NH-3 blocks co-activator binding and also prevents co-repressor binding. More surprisingly, many compounds with extensions behave as full or partial agonists. We present hypotheses to explain both behaviors in terms of dynamic equilibrium of H12 position.